Metaxalone - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for metaxalone and what is the scope of patent protection?
Metaxalone
is the generic ingredient in two branded drugs marketed by Actavis Labs Fl Inc, Amneal Pharms, Ingenus Pharms Llc, Lannett Co Inc, Mountain, Primus Pharms, Rising, Sandoz, Sciegen Pharms Inc, and King Pharms, and is included in ten NDAs. There are two patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.Metaxalone has eight patent family members in seven countries.
There are twenty drug master file entries for metaxalone. Thirty-four suppliers are listed for this compound.
Summary for metaxalone
International Patents: | 8 |
US Patents: | 2 |
Tradenames: | 2 |
Applicants: | 10 |
NDAs: | 10 |
Drug Master File Entries: | 20 |
Finished Product Suppliers / Packagers: | 34 |
Raw Ingredient (Bulk) Api Vendors: | 118 |
Clinical Trials: | 3 |
Patent Applications: | 3,659 |
Drug Prices: | Drug price trends for metaxalone |
Drug Sales Revenues: | Drug sales revenues for metaxalone |
What excipients (inactive ingredients) are in metaxalone? | metaxalone excipients list |
DailyMed Link: | metaxalone at DailyMed |
Recent Clinical Trials for metaxalone
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Primus Pharmaceuticals | Phase 4 |
Illumination Health | Phase 4 |
Rothman Institute Orthopaedics | N/A |
Pharmacology for metaxalone
Drug Class | Muscle Relaxant |
Physiological Effect | Centrally-mediated Muscle Relaxation |
Paragraph IV (Patent) Challenges for METAXALONE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
SKELAXIN | Tablets | metaxalone | 800 mg | 013217 | 1 | 2004-11-04 |
US Patents and Regulatory Information for metaxalone
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sciegen Pharms Inc | METAXALONE | metaxalone | TABLET;ORAL | 207466-001 | Aug 31, 2017 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Sciegen Pharms Inc | METAXALONE | metaxalone | TABLET;ORAL | 207466-002 | Mar 13, 2020 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Primus Pharms | METAXALONE | metaxalone | TABLET;ORAL | 022503-001 | Jun 1, 2015 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for metaxalone
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
King Pharms | SKELAXIN | metaxalone | TABLET;ORAL | 013217-001 | Approved Prior to Jan 1, 1982 | ⤷ Sign Up | ⤷ Sign Up |
King Pharms | SKELAXIN | metaxalone | TABLET;ORAL | 013217-003 | Aug 30, 2002 | ⤷ Sign Up | ⤷ Sign Up |
King Pharms | SKELAXIN | metaxalone | TABLET;ORAL | 013217-003 | Aug 30, 2002 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for metaxalone
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
World Intellectual Property Organization (WIPO) | 2007094825 | ⤷ Sign Up | |
South Korea | 20220025815 | 용량이 감소된 메탁살론 제형 | ⤷ Sign Up |
Canada | 2626027 | PRODUITS A BASE DE METAXALONE, PROCEDE DE PREPARATION ET PROCEDE D'UTILISATION (METAXALONE PRODUCTS, METHOD OF MANUFACTURE, AND METHOD OF USE) | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.